Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy

Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1635-44. doi: 10.1152/ajpheart.2000.279.4.H1635.

Abstract

We compared the role of the Raf-1/mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MEK)/extracellular signal-regulated protein kinase (ERK)/p90(RSK) cascade in gp130-mediated cardiac hypertrophy with the contribution of the Janus kinase (JAK)/signal transduction and activation of transcription (STAT) and phosphatidylinositide 3-kinase (PI3-K) pathways. Primary cultured neonatal rat cardiomyocytes were stimulated with leukemia inhibitory factor (LIF). LIF sequentially activated Raf-1, MEK1/2, ERK1/2, and p90(RSK). We used PD-98059 (a specific MEK inhibitor), AG-490 (a JAK2 inhibitor), and wortmannin (a PI3-K inhibitor) to confirm that this cascade was independent of the JAK/STAT and PI3-K/p70 S6 kinase (S6K) pathways. PD-98059, AG-490, and wortmannin suppressed the LIF-induced increase in [(3)H]phenylalanine uptake by 54.7, 21.5, and 25.6%, respectively, and inhibited the increase in cell area by 61.2, 42.8, and 39.2%, respectively. Reorganization of myofilaments was predominantly suppressed by AG-490. LIF-induced expression of c-fos, brain natriuretic peptide, and skeletal alpha-actin mRNA was markedly suppressed by PD-98059 and moderately suppressed by wortmannin and AG-490. Atrial natriuretic peptide was significantly suppressed by AG-490. These findings indicate that this pathway is critically involved in protein synthesis, induction of c-fos, brain natriuretic peptide, and skeletal alpha-actin expression and is partially involved in myofilament reorganization and atrial natriuretic peptide induction in gp130-mediated cardiac hypertrophy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / pharmacology
  • Animals
  • Antigens, CD / physiology*
  • Cardiomegaly / enzymology*
  • Cardiomegaly / etiology*
  • Cell Size / drug effects
  • Cells, Cultured
  • Cytokine Receptor gp130
  • Flavonoids / pharmacology
  • Genetic Markers
  • Growth Inhibitors / pharmacology
  • Interleukin-6*
  • Leukemia Inhibitory Factor
  • Lymphokines / pharmacology
  • Membrane Glycoproteins / physiology*
  • Mitogen-Activated Protein Kinases / metabolism*
  • Myocardium / cytology
  • Myocardium / metabolism
  • Phenylalanine / pharmacokinetics
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Protein-Tyrosine Kinases / metabolism*
  • Proto-Oncogene Proteins c-raf / metabolism
  • Rats
  • Rats, Wistar
  • Ribosomal Protein S6 Kinases / metabolism
  • Signal Transduction / physiology*
  • Trans-Activators / metabolism*
  • Tyrphostins / pharmacology
  • Wortmannin

Substances

  • Androstadienes
  • Antigens, CD
  • Flavonoids
  • Genetic Markers
  • Growth Inhibitors
  • Il6st protein, rat
  • Interleukin-6
  • Leukemia Inhibitory Factor
  • Lymphokines
  • Membrane Glycoproteins
  • Trans-Activators
  • Tyrphostins
  • alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • Cytokine Receptor gp130
  • Phenylalanine
  • Phosphatidylinositol 3-Kinases
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-raf
  • Ribosomal Protein S6 Kinases
  • Mitogen-Activated Protein Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Wortmannin